Oriental Taihua Launches Home-Based Cardiovascular Risk Detection Technology to Shift from Treatment to Prevention

According to the Report on Cardiovascular Diseases in China released in August 2015, the prevalence of hypertension among Chinese adults reached 25.5% in 2014, meaning that 25.5 out of every 100 individuals aged 18 and older suffered from hypertension. In contrast, the national prevalence of hypertension was only 5% in 1958. Currently, there are a total of 290 million people with cardiovascular disease in China, of whom 270 million have hypertension.

To better control the risk of cardiovascular disease, Dongfang Taihua released its home-based testing technology for cardiovascular risk events in Beijing on March 22. At the launch event, Wu Wei, Chairman of Dongfang Taihua, introduced this home-based testing technology and presented the company’s risk warning solutions for cardiovascular risk events.

Speech by Wu Wei, Chairman of Dongfang Taihua

The three most critical components of Dongfang Taihua’s home-based testing technology for cardiovascular risk events are cloud-based data management, device precision, and platform specialization.

First, the rapid development of the Internet, particularly mobile internet, has provided a favorable environment for “cloud-based data management.” The Taikong series of ECG and blood pressure monitoring devices are capable of cloud-enabled data processing, allowing test results to be uploaded in real time to the service platform and shared with family and friends.

Secondly, the "Taikong" series of ECG and blood pressure monitoring devices produced by Oriental Taihua have all obtained CFDA certification and are nationally recognized as Class II medical devices. These three products are simple and convenient, featuring user-friendly applications suitable for individuals of all ages and cultural backgrounds, while also supporting sharing among family members or even larger groups. The three devices are as follows:

Taikong Single-Channel ECG Recorder (Taikong Xinyi): Featuring a leadless design, it eliminates the hassle of removing clothing and offers convenient wearability. It can effectively detect electrocardiographic changes such as arrhythmias and ST-T segment alterations in relevant regions. This is a CFDA-certified wearable single-channel ECG recorder for home use.

Taikong Voice-Enabled Ambulatory Blood Pressure Monitor: Featuring a wearable design, it enables measurements independent of a smartphone and provides voice announcements of results. It supports 24-hour ambulatory blood pressure monitoring as well as occasional spot-check measurements. The 24-hour blood pressure trend chart facilitates the assessment of risks associated with hypertension, target organ damage, and cardiovascular and cerebrovascular diseases, thereby aiding in the formulation of medication plans.

Taikong 12-Lead ECG Monitor: Designed for use with ergonomic electrode pads, it is highly portable. By integrating ECG data with typical or atypical clinical symptoms and comparing them against the user’s ECG template, the device accurately identifies changes in the ST-T segment and other detailed features associated with acute myocardial infarction and stroke (including cerebral hemorrhage and cerebral infarction). In the event of severe cardiac issues, the device can rapidly upload data to the service platform.

The physician service platform is another critical component in the implementation of Dongfang Taihua’s home-based detection technology for cardiovascular disease risk events.To enhance the professional depth and service quality of its physician service platform, Dongfang Taihua has specially appointed Professor Guo Jihong, currently a Professor, Chief Physician, Doctoral Supervisor, Deputy Director of the Department of Cardiology, and Director of the Cardiac Electrophysiology Laboratory at Peking University People’s Hospital, as its Chief Medical Advisor.

During the clinical trial period spanning more than one year, Dongfang Taihua provided cardiovascular disease risk early warning services to over 15,000 individuals; the service platform made more than 40,000 alert calls to users; over 500 patients sought timely medical attention at hospitals; and nine users received prompt treatment within the “golden hour” for acute myocardial infarction.

The introduction of Dongfang Taihua’s home-based testing technology for cardiovascular risk events is shifting the management of cardiovascular disease from a hospital-centric treatment model to a home-focused risk prevention model. This approach not only provides effective early warnings for high-risk individuals before disease onset, thereby preventing life-threatening adverse events, but also enables timely identification of emerging cardiovascular trends, facilitating early detection, early intervention, and risk mitigation. For patients who have already been diagnosed with cardiovascular disease and undergone hospital treatment, Dongfang Taihua has also launched a “Direct Doctor-Patient Link” management program during post-discharge rehabilitation. This program emphasizes one-on-one scientific management by attending physicians, aiming to accelerate recovery and minimize the risk of recurrence.

Previously, at the launch of the “Analysis Report on Intelligent Hardware in the Cardiovascular Field at Home and Abroad,” VCBeat interviewed Dongfang Taihua and published an article titled “[Cardiovascular Series Report 1] Dongfang Taihua: Making Professional Medical Equipment Accessible to the General Public》. Recently, the "Analysis Report on Intelligent Hardware in the Cardiovascular Field at Home and Abroad" was officially released. This report is another research outcome from VCBeat Eggshell Research Institute, following the "Medical Imaging Report," that provides insight into future trends in healthcare innovation within a specialized sector. To compile this report, VCBeat collected hundreds of intelligent hardware products in the cardiovascular field from both domestic and international markets, and screened out 140 mainstream intelligent hardware devices. These products involve a total of 130 companies, with each product analyzed across at least 22 data dimensions. The final result is a comprehensive study spanning over 70 pages. For ordering information, please seeLink。